Natera, Inc. (NTRA) Covered Calls
Natera, Inc. is a global leader in cell-free DNA (cfDNA) testing and precision medicine. The company leverages proprietary molecular biology and bioinformatics to provide advanced genetic diagnostics across three core areas: women’s health, oncology, and organ health. By analyzing tiny fragments of DNA circulating in a patient’s blood, Natera’s tests offer non-invasive, highly accurate insights to inform clinical decision-making and personalized treatment.
You can sell covered calls on Natera, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for NTRA (prices last updated Fri 11:10 AM ET):
| Natera, Inc. (NTRA) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 198.25 | -4.48 | 198.26 | 199.00 | 156K | - | 29 |
| Covered Calls For Natera, Inc. (NTRA) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Apr 17 | 200 | 9.00 | 190.00 | 4.7% | 59.2% | |
| May 15 | 200 | 15.80 | 183.20 | 8.6% | 55.1% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Core Business and Products
Natera’s diagnostic platform is built on advanced cfDNA technology, which allows for detection down to a single molecule in a blood sample. Its flagship portfolio includes Panorama (prenatal screening), Signatera (a tumor-informed assay for tracking minimal residual disease in cancer patients), and Prospera (an organ transplant rejection assessment test). The company integrates these proprietary tests with AI-driven bioinformatics to support longitudinal patient monitoring and personalized therapy.
Competitive Landscape
Natera operates in a high-stakes, innovation-driven market where it faces intense competition from established diagnostic giants and specialized genomics firms:
- Guardant Health (GH): A primary competitor in the oncology space, particularly for liquid biopsy and MRD testing, competing directly with Natera’s Signatera platform.
- Myriad Genetics (MYGN): A long-standing competitor in hereditary cancer and reproductive genetic testing, offering a broad range of clinical-grade genetic diagnostics.
- CareDx (CDNA): A direct rival in the transplant diagnostic space, competing head-to-head with Natera’s Prospera test for organ health and rejection monitoring.
Strategic Outlook and Innovation
Natera’s strategy focuses on deepening clinical adoption and expanding payer coverage for its core tests. By heavily investing in R&D and AI-driven data collaborations—including partnerships for high-performance computing—Natera is positioning its platform as the foundation for modern precision medicine. The stock acts as a high-growth biotech play, balancing the significant market potential of its diagnostic tests with the operational demands of scaling clinical laboratory services globally.
| Top 10 Open Interest For Apr 17 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | SLV covered calls | 6. | SPY covered calls | 1. | NVCR covered calls | |
| 2. | EEM covered calls | 7. | QQQ covered calls | 2. | TROX covered calls | |
| 3. | NVDA covered calls | 8. | HYG covered calls | 3. | REPL covered calls | |
| 4. | KWEB covered calls | 9. | EWZ covered calls | 4. | BTU covered calls | |
| 5. | GLD covered calls | 10. | XLE covered calls | 5. | AEHR covered calls | |
Want more examples? NTR Covered Calls | NTRS Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
